Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:EOLSNASDAQ:KALVNASDAQ:SPPI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$3.94$3.62$1.42▼$11.97$234.08M1.51584,061 shs462,580 shsEOLSEvolus$11.46-0.3%$13.48$7.07▼$15.43$663.99M1.45610,548 shs287,750 shsKALVKalVista Pharmaceuticals$10.49+1.4%$12.45$7.21▼$16.88$442.57M0.88725,107 shs363,774 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+0.77%-0.76%+36.81%+29.61%-56.61%EOLSEvolus-1.71%-1.20%-16.67%-2.87%+36.90%KALVKalVista Pharmaceuticals-7.67%-11.16%-7.01%-19.46%+28.57%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+12.45%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.426 of 5 stars3.52.00.00.01.12.50.0EOLSEvolus3.8801 of 5 stars3.52.00.03.51.92.50.6KALVKalVista Pharmaceuticals4.0958 of 5 stars3.51.00.04.63.22.50.6SPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33136.89% UpsideEOLSEvolus3.00Buy$20.6079.76% UpsideKALVKalVista Pharmaceuticals3.00Buy$26.33151.03% UpsideSPPISpectrum Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest ALDX, KALV, SPPI, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.001/29/2024EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AEOLSEvolus$202.09M3.29N/AN/A($0.36) per share-31.83KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)EOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/7/2024 (Confirmed)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest ALDX, KALV, SPPI, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AEOLSEvolus-$0.0650N/A+$0.0650N/AN/AN/A 3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64EOLSEvolusN/A2.332.10KALVKalVista PharmaceuticalsN/A5.445.44SPPISpectrum PharmaceuticalsN/A2.712.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%EOLSEvolus90.69%KALVKalVista PharmaceuticalsN/ASPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%EOLSEvolus5.40%KALVKalVista Pharmaceuticals12.30%SPPISpectrum Pharmaceuticals2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million54.60 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableALDX, KALV, SPPI, and EOLS HeadlinesSourceHeadlineSpectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride saltspharmaceutical-technology.com - April 24 at 10:28 AMAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTmarkets.businessinsider.com - February 21 at 11:54 PMLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinemarkets.businessinsider.com - February 21 at 1:34 PMLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinskymarkets.businessinsider.com - February 8 at 2:32 PMAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 5 at 2:12 PMGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)stockhouse.com - February 1 at 1:26 PMCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 1 at 1:16 AMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming Deadlinestockhouse.com - January 30 at 10:18 AMINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) Investorstmcnet.com - January 26 at 6:41 PMLobbying revenues continued climbing amid stalled Hill actionpolitico.com - January 23 at 7:48 PMINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinestockhouse.com - January 13 at 10:52 PMEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 12 at 6:07 AMVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 10 at 10:13 AMSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investorsmsn.com - January 9 at 8:33 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTmarkets.businessinsider.com - November 9 at 7:46 PM$19.30+ Bn Neutropenia Treatment Market to Grow at 5.4% CAGR, Globally, by 2027pharmiweb.com - November 8 at 7:16 PMDisney offers streaming service discount amid Spectrum blackoutctpost.com - September 8 at 6:23 PMAnalyzing Spectrum Pharmaceuticals Inc. (SPPI) After Recent Trading Activityknoxdaily.com - July 31 at 5:06 PMSpectrum Pharmaceuticals Inc. [SPPI] CFO makes an insider sale of 32,387 shares worth 35,496.knoxdaily.com - July 28 at 10:55 AMBuy Spectrum Pharmaceuticals For Exposure To Assertio Holdingsseekingalpha.com - July 24 at 6:02 AMPotential Price Increase for Spectrum Pharmaceuticals Inc. (SPPI) After Recent Insider Activityknoxdaily.com - July 19 at 7:14 PMNegative sentiment towards SPPI reflected by a jump of 6.23% in short interestknoxdaily.com - July 14 at 9:14 PMSpectrum Pharmaceuticals Inc. [SPPI] Investment Appeal on the Riseknoxdaily.com - July 11 at 7:15 PMSpectrum Pharmaceuticals (NASDAQ: SPPI)fool.com - July 8 at 8:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.